Renal Cell Carcinoma: Translating Trial Data to Real-World Practice

In this segment, Dr. Elizabeth Plimack and Dr. Sundhar Ramalingam discuss the relationship between clinical trial outcomes and real-world experience in the management of renal cell carcinoma. Dr. Ramalingam highlights that while clinical trials provide essential evidence for first-line treatment strategies, they often include carefully selected patient populations that may not fully represent the diversity seen in routine clinical practice. The conversation explores how factors such as comorbidities, performance status, and broader patient variability can influence treatment outcomes outside of controlled trial settings. Dr. Ramalingam emphasizes the importance of applying trial data thoughtfully, recognizing both its strengths and its limitations. This segment underscores the need to bridge the gap between clinical evidence and real-world application to ensure that treatment decisions in renal cell carcinoma remain individualized and practical.